XAIR Key Statistics, Chart & Performance
The current stock price of XAIR is 0.829 USD. In the past month the price decreased by -27.28%. In the past year, price decreased by -89.29%.
XAIR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.46 | 220.91B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.79 | 209.96B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.44 | 146.24B | ||
| SYK | STRYKER CORP | 27.92 | 140.63B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.86B | ||
| IDXX | IDEXX LABORATORIES INC | 56.67 | 57.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.01 | 49.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.68 | 39.07B | ||
| RMD | RESMED INC | 25.07 | 36.23B | ||
| DXCM | DEXCOM INC | 37.69 | 27.34B | ||
| PODD | INSULET CORP | 65.46 | 21.05B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.45 | 18.37B |
Related stock screener links
About XAIR
Company Profile
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Company Info
BEYOND AIR INC
900 Stewart Ave, Suite 301
Garden City NEW YORK 11530 US
CEO: Steven Lisi
Employees: 61
Phone: 15166658200
BEYOND AIR INC / XAIR FAQ
What does XAIR do?
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Can you provide the latest stock price for BEYOND AIR INC?
The current stock price of XAIR is 0.829 USD. The price increased by 4.94% in the last trading session.
Does BEYOND AIR INC pay dividends?
XAIR does not pay a dividend.
What is the ChartMill technical and fundamental rating of XAIR stock?
XAIR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting XAIR stock to perform?
11 analysts have analysed XAIR and the average price target is 9.18 USD. This implies a price increase of 1007.36% is expected in the next year compared to the current price of 0.829.
What is the expected growth for XAIR stock?
The Revenue of BEYOND AIR INC (XAIR) is expected to grow by 111.92% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BEYOND AIR INC?
BEYOND AIR INC (XAIR) has a market capitalization of 6.64M USD. This makes XAIR a Nano Cap stock.
XAIR Technical Analysis
XAIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XAIR. XAIR has a bad profitability rating. Also its financial health evaluation is rather negative.
XAIR Financial Highlights
Over the last trailing twelve months XAIR reported a non-GAAP Earnings per Share(EPS) of -7.58. The EPS increased by 73.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -118.51% | ||
| ROE | -288.2% | ||
| Debt/Equity | 0.79 |
XAIR Forecast & Estimates
11 analysts have analysed XAIR and the average price target is 9.18 USD. This implies a price increase of 1007.36% is expected in the next year compared to the current price of 0.829.
For the next year, analysts expect an EPS growth of 78.29% and a revenue growth 111.92% for XAIR